fluorescein has been researched along with cyclosporine in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (15.38) | 18.2507 |
| 2000's | 13 (33.33) | 29.6817 |
| 2010's | 13 (33.33) | 24.3611 |
| 2020's | 7 (17.95) | 2.80 |
| Authors | Studies |
|---|---|
| Benítez del Castillo, JM; del Aguila, C; Duran, S; García Sánchez, J; Hernandez, J | 1 |
| Amador, A; Kahan, BD; Rutzky, LP; Welsh, M | 1 |
| Benítez del Castillo, JM; Castillo, A; del Aguila, C; Durán, S; García-Sanchez, J; Otero, M; Toledano, N | 1 |
| Hudson, LC; Hughes, CS; Manaugh, CA; Price, GS; Vaden, SL | 1 |
| Le, XC; Ma, M; Xing, JZ; Yatscoff, R; Ye, L | 1 |
| Allentoff, AJ; Duelfer, T; Liang, H; Mandiyan, S; Sytwu, II; Vlattas, I; Wennogle, LP; Yuryev, A | 1 |
| Kawabe, T; Nada, S; Ryu, S; Yamaguchi, A | 1 |
| Bolle, JF; Bongard, O; Bounameaux, H; Lemoine, R; Leski, M; Weimer, D | 1 |
| Lamas, S; Navarro-Antolin, J | 1 |
| Dohgu, S; Higuchi, S; Katamine, S; Kataoka, Y; Naito, M; Niwa, M; Sawada, Y; Shirabe, S; Takata, F; Tsuruo, T; Yamauchi, A | 1 |
| Dohgu, S; Egawa, T; Kai, M; Kataoka, Y; Naito, M; Nakagawa, S; Niwa, M; Sawada, Y; Takata, F; Tsuruo, T; Yamauchi, A | 1 |
| Kusel, JR; Liu, JF | 1 |
| Biser, SA; Bloom, AH; Donnenfeld, ED; Doshi-Carnevale, S; Perry, HD; Solomon, R | 1 |
| Jiang, J; Johnson, DD; Kati, WM; Liu, Y; Reddy, RD; Richardson, PL | 1 |
| Farjo, QA; Gupta, A; Lelli, GJ; Mian, SI; Musch, DC; Nairus, TM | 1 |
| Dohgu, S; Kataoka, Y; Naito, M; Nakagawa, S; Shuto, H; Sumi, N; Takata, F; Tsuruo, T; Yamauchi, A | 1 |
| Dohgu, S; Kataoka, Y; Naito, M; Nakagawa, S; Nishioku, T; Shuto, H; Sumi, N; Takata, F; Tsuruo, T; Yamauchi, A | 1 |
| Donnenfeld, ED; Greenman, HE; Perry, AR; Perry, HD; Savage, HE; Solomon, R; Wittpenn, JR | 1 |
| Dana, R; Dastjerdi, MH; Hamrah, P | 1 |
| Malta, JB; Mian, SI; Musch, DC; Rhoades, W; Shtein, RM; Soong, HK; Sugar, A | 1 |
| Mahawong, W; Prabhasawat, P; Tesavibul, N | 1 |
| Liu, X; Roberts, MS; Thorling, CA; Weiss, M | 1 |
| Amparo, F; Dana, R; Hamrah, P; Jin, Y; Schaumberg, DA | 1 |
| Dutescu, RM; Merkel, OM; Panfil, C; Schrage, N | 1 |
| Chiriano, G; Gurny, R; Kalia, YN; Lapteva, M; Möller, M; Mondon, K; Patmanidis, I; Santer, V; Scapozza, L | 1 |
| Gong, L; Lin, T | 1 |
| Acir, NO; Cetinkaya, S; Cetinkaya, YF; Dadaci, Z; Mestan, E; Yener, HI | 1 |
| Amrane, M; Baudouin, C; de la Maza, MS; Figueiredo, FC; Garrigue, JS; Ismail, D; Leonardi, A | 1 |
| Barabino, S; Baudouin, C; Daull, P; Docquier, M; Feraille, L; Garrigue, JS; Kessal, K; Parsadaniantz, SM | 1 |
| Beckert, M; Ciolino, JB; Jentsch, G; Krösser, S; Lonsdale, JD; Moreira, HR; Ousler, GW; Steven, P; Torkildsen, GL; Wirta, DL | 1 |
| Choi, YH; Kim, DH; Kim, MK; Kim, Y; Paik, HJ | 1 |
| Adhikari, N; Bang, SP; Jun, JH; Kim, H; Kim, JY; Lee, DC; Lee, HG; Neupane, S; Son, MJ; Yeon, CY | 1 |
| Cox, SM; Nichols, KK; Osei, KA | 1 |
| Boehmer, BE; Ciolino, JB; Krösser, S; McLaurin, E; Meides, AS; Ousler, GW; Schlüter, T; Sheppard, JD; Usner, D; Wirta, DL | 1 |
| Sang Min, J; Shin, D | 1 |
| Jiang, X; Jie, Y; Jin, X; Li, X; Peng, W; Wu, M; You, Z; Zhou, Q; Zhou, S; Zhu, L | 1 |
| Birangal, S; Chaudhari, P; Ghate, V; Kodoth, AK; Lewis, SA; Mallela, LS; Mavlankar, N; Nampoothiri, M; Pal, A; Roy, S | 1 |
| Akpek, EK; Ciolino, JB; Downing, JE; Krösser, S; Meides, AS; Sheppard, JD; Tauber, J; Wirta, DL | 1 |
| Bhargava, R; Pandey, K; Rajpoot, M; Singh, D | 1 |
9 trial(s) available for fluorescein and cyclosporine
| Article | Year |
|---|---|
Cyclosporine toxicity in renal transplant recipients detected by nailfold capillaroscopy with Na-fluorescein.
Topics: Adult; Biopsy; Blood Flow Velocity; Capillaries; Contrast Media; Cyclosporine; Female; Fluorescein; Graft Rejection; Humans; Immunosuppressive Agents; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Laser-Doppler Flowmetry; Male; Middle Aged; Nails; Skin; Skin Temperature; Ultrasonography | 2000 |
Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction.
Topics: Adult; Blepharitis; Contrast Media; Cyclosporine; Fluorescein; Follow-Up Studies; Humans; Immunosuppressive Agents; Meibomian Glands; Ophthalmic Solutions; Prospective Studies; Tears; Treatment Outcome | 2006 |
A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction.
Topics: Administration, Topical; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Emulsions; Eyelid Diseases; Female; Fluorescein; Humans; Immunosuppressive Agents; Male; Meibomian Glands; Middle Aged; Ophthalmic Solutions; Prospective Studies; Rose Bengal; Staining and Labeling; Tears; Treatment Outcome | 2012 |
Topical fluorometholone treatment for ocular dryness in patients with Sjögren syndrome: a randomized clinical trial in China.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; China; Cyclosporine; Female; Fluorescein; Fluorometholone; Humans; Hyaluronic Acid; Male; Middle Aged; Ophthalmic Solutions; Sjogren's Syndrome; Viscosupplements | 2015 |
One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
Topics: Adult; Aged; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Emulsions; Female; Fluorescein; Humans; Immunosuppressive Agents; Keratitis; Male; Middle Aged; Ophthalmic Solutions; Tears | 2017 |
A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Topics: Administration, Ophthalmic; Aged; Cornea; Cyclosporine; Double-Blind Method; Drug Compounding; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Quality of Life; Sickness Impact Profile; Tears; Treatment Outcome; Visual Analog Scale | 2019 |
A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study.
Topics: Administration, Ophthalmic; Adolescent; Adult; Aged; Aged, 80 and over; Conjunctiva; Cornea; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Staining and Labeling; Treatment Outcome; Water | 2021 |
Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial.
Topics: Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Fluorescein; Gels; Humans; Immunosuppressive Agents; Ophthalmic Solutions; Tears; Treatment Outcome | 2022 |
Safety and efficacy of cyclosporine (0.05% versus 0.09%) in dry eye disease. Is it the strength of cyclosporin that really matters?
Topics: Conjunctiva; Cyclosporine; Dry Eye Syndromes; Fluorescein; Humans | 2022 |
30 other study(ies) available for fluorescein and cyclosporine
| Article | Year |
|---|---|
Influence of topically applied cyclosporine A in olive oil on corneal epithelium permeability.
Topics: Administration, Topical; Adult; Cell Membrane Permeability; Cornea; Corneal Diseases; Cyclosporine; Emulsions; Female; Fluorescein; Fluoresceins; Fluorophotometry; Humans; Male; Olive Oil; Ophthalmic Solutions; Plant Oils; Pruritus | 1994 |
Production of interference in the TDx polarization immunoassay by fluorescein angiography.
Topics: Angiography; Cyclosporine; Drug Monitoring; Fluorescein; Fluoresceins; Fluorescence; Fluorescence Polarization Immunoassay; Injections, Intravenous | 1993 |
Influence of topical cyclosporine A and dissolvent on corneal epithelium permeability of fluorescein.
Topics: Administration, Topical; Adolescent; Adult; Cell Membrane Permeability; Cornea; Cyclosporine; Epithelium; Female; Fluorescein; Fluoresceins; Fluorophotometry; Humans; Immunosuppressive Agents; Male; Oils; Ophthalmic Solutions; Pharmaceutical Vehicles; Reference Values | 1995 |
Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain; Cisplatin; Cyclosporine; Doxorubicin; Evans Blue; Fluorescein; Horseradish Peroxidase; Injections, Intravenous; Injections, Subcutaneous; Male; Platinum; Rats; Rats, Inbred F344; Testis; Tissue Distribution | 1998 |
Competitive immunoassay for cyclosporine using capillary electrophoresis with laser induced fluorescence polarization detection.
Topics: Antibodies; Cross Reactions; Cyclosporine; Electrophoresis, Capillary; Fluorescein; Fluorescence Polarization; Fluorescent Dyes; Humans; Immunoassay; Lasers; Organ Transplantation; Sensitivity and Specificity | 1998 |
Understanding the cellular uptake of phosphopeptides.
Topics: Acetic Anhydrides; Acetylation; Amines; Animals; Cell Line; Cell Membrane; Chromatography, High Pressure Liquid; Cyclosporine; Erythrocytes; Fluorescein; Fluorescent Dyes; Humans; Ions; Octanols; Phosphopeptides; Phosphorylation; Phosphotyrosine; src Homology Domains; Water | 1999 |
Identification of basic residues involved in drug export function of human multidrug resistance-associated protein 2.
Topics: Alanine; Amino Acid Sequence; Amino Acids; Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily B; Binding Sites; Bridged Bicyclo Compounds; Carrier Proteins; Cell Membrane; CHO Cells; COS Cells; Cricetinae; Cyclosporine; Fluorescein; Glutathione; Humans; Immunoblotting; Membrane Transport Proteins; Microscopy, Confocal; Microscopy, Fluorescence; Molecular Sequence Data; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Mutagenesis, Site-Directed; Mutation; Protein Transport; Time Factors | 2000 |
Nitrosative stress by cyclosporin A in the endothelium: studies with the NO-sensitive probe diaminofluorescein-2/diacetate using flow cytometry.
Topics: Animals; Aorta; Cattle; Cells, Cultured; Cyclosporine; Endothelium, Vascular; Flow Cytometry; Fluorescein; Indicators and Reagents; Kinetics; NG-Nitroarginine Methyl Ester; Nitric Oxide | 2001 |
Uptake and efflux of quinacrine, a candidate for the treatment of prion diseases, at the blood-brain barrier.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cation Transport Proteins; Cell Line; Cell Membrane; Cell Polarity; Cimetidine; Cyclosporine; Endothelial Cells; Fluorescein; Membrane Potentials; Mice; Prion Diseases; Quinacrine; Tetraethylammonium; Verapamil | 2004 |
Nitric oxide mediates cyclosporine-induced impairment of the blood-brain barrier in cocultures of mouse brain endothelial cells and rat astrocytes.
Topics: Animals; Animals, Newborn; Astrocytes; ATP Binding Cassette Transporter, Subfamily B; Blood-Brain Barrier; Brain; Cell Line, Transformed; Cell Line, Tumor; Cell Membrane Permeability; Cell Survival; Coculture Techniques; Cyclosporine; Dose-Response Relationship, Drug; Endothelial Cells; Enzyme Inhibitors; Fluorescein; Mice; Mice, Inbred BALB C; Nitric Oxide; Nitric Oxide Synthase; omega-N-Methylarginine; Rats; Rats, Wistar; Rhodamine 123 | 2004 |
In vitro effect of cyclosporine A on juvenile Schistosoma mansoni labeled by AF18 (5-N-octadecanoyl aminofluorescein).
Topics: Animals; Cyclosporine; Dose-Response Relationship, Drug; Fluorescein; Membrane Fluidity; Microscopy, Fluorescence; Schistosoma mansoni | 2004 |
A fluorescence polarization-based assay for peptidyl prolyl cis/trans isomerase cyclophilin A.
Topics: Binding Sites; Binding, Competitive; Cyclophilin A; Cyclosporine; Cyclosporins; Drug Design; Enzyme Inhibitors; Fluorescein; Fluorescence Polarization; Humans; In Vitro Techniques; Kinetics; Molecular Structure; Recombinant Proteins | 2006 |
Ophthalmic cyclosporine use in ocular GVHD.
Topics: Administration, Topical; Adolescent; Adult; Aged; Cyclosporine; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Fluorophotometry; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Retrospective Studies | 2006 |
Inhibition of transforming growth factor-beta production in brain pericytes contributes to cyclosporin A-induced dysfunction of the blood-brain barrier.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain; Cell Membrane Permeability; Cells, Cultured; Cyclosporine; Down-Regulation; Endothelial Cells; Fluorescein; Humans; Mice; Mice, Inbred BALB C; Pericytes; Transforming Growth Factor beta1 | 2007 |
Adverse effect of cyclosporin A on barrier functions of cerebral microvascular endothelial cells after hypoxia-reoxygenation damage in vitro.
Topics: Albumins; Animals; Blood-Brain Barrier; Capillary Permeability; Cell Line, Transformed; Cyclosporine; Endothelial Cells; Evans Blue; Fluorescein; Fluorescent Dyes; Glucose; Hypoxia; Immunosuppressive Agents; In Vitro Techniques; Mice; Mice, Inbred BALB C; Oxygen | 2007 |
Evaluation of topical cyclosporine for the treatment of dry eye disease.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Cyclosporine; Drug Evaluation; Dry Eye Syndromes; Female; Fluorescein; Fluorophotometry; Humans; Immunosuppressive Agents; Lissamine Green Dyes; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Tears | 2008 |
High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen.
Topics: Administration, Topical; Adult; Aged; Cohort Studies; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorescein; Fluorescent Dyes; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Retreatment; Retrospective Studies; Severity of Illness Index; Sjogren's Syndrome; Staining and Labeling; Xerophthalmia | 2009 |
Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%.
Topics: Administration, Topical; Adolescent; Adult; Aged; Bone Marrow Transplantation; Child; Child, Preschool; Cyclosporine; Dry Eye Syndromes; Female; Fluorescein; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lissamine Green Dyes; Male; Middle Aged; Neoplasms; Retrospective Studies; Surveys and Questionnaires; Tears; Treatment Outcome | 2010 |
Functional characterization of hepatic transporters using intravital microscopy.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Cyclosporine; Fluorescein; Fluorescent Dyes; Liver; Male; Microscopy, Fluorescence, Multiphoton; Models, Biological; Organic Anion Transporters; Rats; Rats, Wistar; Rhodamine 123; Rifampin | 2013 |
What is the value of incorporating tear osmolarity measurement in assessing patient response to therapy in dry eye disease?
Topics: Antirheumatic Agents; Blood; Cornea; Cyclosporine; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Fluorophotometry; Glucocorticoids; Humans; Immunosuppressive Agents; Interleukin 1 Receptor Antagonist Protein; Lubricants; Male; Middle Aged; Ophthalmic Solutions; Osmolar Concentration; Retrospective Studies; Surveys and Questionnaires; Tears | 2014 |
Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery.
Topics: Administration, Topical; Alkanes; Animals; Castor Oil; Cornea; Cyclosporine; Drug Carriers; Eye; Eye Diseases; Fluorescein; Fluorine; Glucose; Inflammation; Kinetics; Lactic Acid; Lipids; Rabbits; Solvents | 2014 |
Targeted cutaneous delivery of ciclosporin A using micellar nanocarriers and the possible role of inter-cluster regions as molecular transport pathways.
Topics: Administration, Cutaneous; Animals; Biological Transport, Active; Cyclosporine; Drug Carriers; Drug Delivery Systems; Fluorescein; Fluorescent Dyes; Humans; Immunosuppressive Agents; In Vitro Techniques; Micelles; Models, Molecular; Nanoparticles; Particle Size; Skin Absorption; Swine | 2014 |
The course of dry eye after phacoemulsification surgery.
Topics: Aged; Aged, 80 and over; Chronic Disease; Cyclosporine; Dry Eye Syndromes; Female; Fluorescein; Fluorophotometry; Humans; Immunosuppressive Agents; Lubricant Eye Drops; Male; Middle Aged; Phacoemulsification; Retrospective Studies; Staining and Labeling; Tears | 2015 |
Modulation of Inflammation-Related Genes in the Cornea of a Mouse Model of Dry Eye upon Treatment with Cyclosporine Eye Drops.
Topics: Administration, Ophthalmic; Animals; Cornea; Cyclosporine; Cytokines; Disease Models, Animal; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Gene Expression Regulation; Genetic Markers; Immunosuppressive Agents; Inflammation; Mice; Mice, Inbred C57BL; Ophthalmic Solutions; Receptors, Cytokine; RNA, Messenger; Tears | 2019 |
Short-Term Effects of Ground-Level Ozone in Patients With Dry Eye Disease: A Prospective Clinical Study.
Topics: Adult; Aged; Cornea; Cross-Sectional Studies; Cyclosporine; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Oxidants, Photochemical; Ozone; Polyphosphates; Prospective Studies; Tears; Uracil Nucleotides | 2019 |
Cyclosporine A eyedrops with self-nanoemulsifying drug delivery systems have improved physicochemical properties and efficacy against dry eye disease in a murine dry eye model.
Topics: Animals; Apoptosis; Cell Count; Conjunctiva; Cyclosporine; Cytokines; Disease Models, Animal; Drug Delivery Systems; Dry Eye Syndromes; Emulsions; Epithelium, Corneal; Fluorescein; Goblet Cells; Hydrogen-Ion Concentration; Inflammation; Ki-67 Antigen; Mice; Nanoparticles; Nephelometry and Turbidimetry; Ophthalmic Solutions; Particle Size; Tears; Treatment Outcome; Viscosity | 2019 |
Dry Eye Disease Practice in Ghana: Diagnostic Perspectives, Treatment Modalities, and Challenges.
Topics: Adult; Cyclosporine; Diagnostic Techniques, Ophthalmological; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Ghana; Humans; Immunosuppressive Agents; Lubricant Eye Drops; Male; Middle Aged; Optometrists; Osmolar Concentration; Practice Patterns, Physicians'; Punctal Plugs; Serum; Surveys and Questionnaires; Tears; Treatment Outcome; Young Adult | 2020 |
Comparison of treatment effects between 4.9% N-acetyl-aspartyl glutamic acid and 0.05% cyclosporine A eye drops in dry eye patients.
Topics: Cyclosporine; Dry Eye Syndromes; Fluorescein; Glutamic Acid; Humans; Meibomian Gland Dysfunction; Meibomian Glands; Ophthalmic Solutions; Retrospective Studies; Tears | 2022 |
Oil-free eye drops containing Cyclosporine A/cyclodextrin/PVA supramolecular complex as a treatment modality for dry eye disease.
Topics: Animals; Chickens; Cornea; Cyclodextrins; Cyclosporine; Dry Eye Syndromes; Female; Fluorescein; Humans; Mice; Ophthalmic Solutions; Scopolamine Derivatives | 2022 |
Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial.
Topics: Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Female; Fluorescein; Humans; Lubricant Eye Drops; Male; Middle Aged; Ophthalmic Solutions; Quality of Life; Tears; Treatment Outcome | 2023 |